unknown
Stage
1
Investors
About
Aquila Bioscience is an R&D company that develops a proprietary Pathogen Capture Technology (PCT) biomimetic platform to capture and neutralise viruses, bacteria and fungi. The company commercialises products such as a decontamination device and a chemical-free ProShield spray and works in glycobiology, glyco-informatics and pathogen filtration applications.
Explore Aquila Bioscience's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.